Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ: ELVN ) with a Buy and raises the price target from $60 to $80.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.